Nuevocor: Valuation, Funding & Investors
Nuevocor is a Singapore-headquartered biotechnology company focused on developing treatments for cardiomyopathies caused by aberrant mechanobiology. The company is advancing its lead candidate, NVC-001, targeting LMNA-related dilated cardiomyopathy, through Phase 1/2 clinical trials to establish clinical proof-of-concept.
Leadership & Board
- Current Number of Employees
- 29
- Current LinkedIn Followers
- 3,253
Latest Estimated Valuation
- Total Amount Raised
- $45M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $45M
- Latest Funding Round
- Series B
Employee Trend
Nuevocor had 29 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.
29Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
Nuevocor had 3,253 followers as of November 9, 2026. The number of followers increased by 33 (1.02%) week-over-week.
3,253Latest Followers Count
33(1.02%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| May 06, 2025 | Series B | $45.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Boehringer Ingelheim Venture Fund | Series B |
| ClavystBio | Series B |
| SEEDS Capital | Series B |
| EDBI | Series B |
| Kurma Partners | Series B |
| Angelini Ventures | Series B |
| Highlight Capital | Series B |
Similar Companies
A snapshot of private companies similar to Nuevocor, helping you discover and navigate related company profiles.
Related News and Analysis
